Leadership & Governance
Guided by a Scientific Advisory Board of key opinion leaders and seasoned executive leadership, Groff North America is establishing the regulatory and scientific framework for botanical pharmaceutical development.
Scientific Advisory Board
Our Scientific Advisory Committee comprises key opinion leaders from top research institutions who have collectively guided dozens of therapeutics through the FDA approval process to commercialization.
To Be Announced
We are currently formalizing our Scientific Advisory Board. The complete roster of key opinion leaders and academic partners will be announced shortly.
Executive Leadership
T.J. Leverte
T.J. comes from a background in investment and corporate finance. He is experienced in the financing and operations of botanical companies.
Chuck McGowan
Chuck McGowan brings more than 20 years of pharmaceutical, medical, and DEA controlled substance regulation experience to the Groff NA team.
Jeff Cary
Jeff Cary manages the business development and sales activities at Groff NA. Experienced in retail business development and management.
Felipe Recalde
Pioneering the molecular breeding program and genomic probe technologies.
DEA Registrations
Groff North America operates under six specific Schedule I DEA registrations, enabling fully compliant research, manufacturing, and global export of controlled botanical substances.
Bulk Manufacturing
Allows for the cultivation, extraction, and processing of federally-legal Cannabis.
Non-Bulk Manufacturing
Allows production of precise dosed forms (Patient Dose Form) for clinical trials and FDA-approved drugs.
Importer
Enables the importation of Cannabis flower, genetics, and extracts from anywhere in the world for US operations.
Exporter
Permits the export of Cannabis flower and preparations to any of the 150+ signatory countries in the UN Single Convention on Narcotics.
Researcher
Authorizes internal research on Cannabis-based therapies and facilitates collaboration with external researchers.
Analytical Lab
Allows commercial testing of Cannabis at the highest possible standards.
Regulatory Heritage
Groff North America has established the federal compliance framework for botanical drug development, executing several historical "firsts" under US federal law.
DEA Registrations Granted
Groff NA Hemplex LLC received its Analytical Lab, Manufacturing (Bulk), Importer, Manufacturing (Dose), and Researcher registrations.
First DEA Quotas & Manufacturing
Received first DEA authorized manufacturer and procurement quotas, and manufactured the first campaign of Bulk material.
First US Transfer to DEA
Successfully executed the first DEA Transfer of domestically cultivated material to the US Drug Enforcement Administration.
First International Import
Successfully imported marijuana internationally (from Canada to Groff NA Hemplex, LLC) as a DEA authorized Importer.
First International Export
Successfully exported marijuana internationally (from Groff NA Hemplex, LLC to Canada) as a DEA authorized Exporter.
Genomic Probe Development
Developed proprietary genomic probe to identify and isolate specific genetic markers for targeted therapeutic production.
First Genetic Export
Successfully executed the first international export of genetics.